Merrimack Pharmaceuticals, Inc.
Hedge Funds Holdings
Last updated:
Merrimack Pharmaceuticals, Inc.‘s stocks are currently a part of 29 hedge funds’ portfolios, which represents 16.56% of the total amount of its stocks outstanding. This makes up a total of 2.24M shares of Merrimack Pharmaceuticals, Inc.. Compared to the previous quarter, the number fell by -70.35% or -5.31M shares fewer. As for the holding position changes, 20.69% (6) of current hedge fund investors increased the number of shares held, 13.79% (4) of current holders sold a part of the shares held, and 6.9% (2) closed the holdings completely. 5 hedge funds are new holders of Merrimack Pharmaceuticals, Inc. stock in Q1 2023, it is 17.24% of total holders.
Hedge funds holding Merrimack Pharmaceuticals (Q2 2018 – Q1 2023)
| Q2 2018 | 67 |
|---|---|
| Q3 2018 | 59 |
| Q4 2018 | 51 |
| Q1 2019 | 49 |
| Q2 2019 | 45 |
| Q3 2019 | 41 |
| Q4 2019 | 41 |
| Q1 2020 | 32 |
| Q2 2020 | 32 |
| Q3 2020 | 32 |
| Q4 2020 | 36 |
| Q1 2021 | 44 |
| Q2 2021 | 42 |
| Q3 2021 | 36 |
| Q4 2021 | 36 |
| Q1 2022 | 39 |
| Q2 2022 | 39 |
| Q3 2022 | 38 |
| Q4 2022 | 46 |
| Q1 2023 | 29 |
Hedge funds changes in Merrimack Pharmaceuticals positions (Q2 2018 – Q1 2023)
| Q2 2018 | 14 | 21 | 19 | 21 | -8 |
|---|---|---|---|---|---|
| Q3 2018 | 5 | 17 | 20 | 12 | 5 |
| Q4 2018 | 8 | 12 | 21 | 16 | -6 |
| Q1 2019 | 6 | 11 | 17 | 8 | 7 |
| Q2 2019 | 4 | 11 | 14 | 7 | 9 |
| Q3 2019 | 4 | 6 | 31 | 8 | -8 |
| Q4 2019 | 5 | 6 | 13 | 5 | 12 |
| Q1 2020 | 1 | 2 | 13 | 10 | 6 |
| Q2 2020 | 4 | 3 | 8 | 4 | 13 |
| Q3 2020 | 3 | 8 | 6 | 3 | 12 |
| Q4 2020 | 7 | 5 | 9 | 3 | 12 |
| Q1 2021 | 9 | 15 | 6 | 1 | 13 |
| Q2 2021 | 5 | 7 | 17 | 7 | 6 |
| Q3 2021 | 1 | 4 | 12 | 7 | 12 |
| Q4 2021 | 4 | 3 | 11 | 4 | 14 |
| Q1 2022 | 4 | 8 | 10 | 1 | 16 |
| Q2 2022 | 2 | 10 | 10 | 2 | 15 |
| Q3 2022 | 3 | 5 | 14 | 4 | 12 |
| Q4 2022 | 13 | 15 | 9 | 5 | 4 |
| Q1 2023 | 5 | 6 | 4 | 2 | 12 |
Hedge funds changes in Merrimack Pharmaceuticals stock options (Q2 2018 – Q1 2023)
| Q2 2018 | 1,631,000 | 352,000 |
|---|---|---|
| Q3 2018 | 195,000 | 233,000 |
| Q4 2018 | 0 | 23,000 |
| Q1 2019 | 110,000 | 49,000 |
| Q2 2019 | 232,000 | 0 |
| Q3 2019 | 214,000 | 114,000 |
| Q4 2019 | 160,000 | 214,000 |
| Q1 2020 | 58,000 | 55,000 |
| Q2 2020 | 367,000 | 0 |
| Q3 2020 | 801,000 | 281,000 |
| Q4 2020 | 3,311,000 | 474,000 |
| Q1 2021 | 669,000 | 991,000 |
| Q2 2021 | 38,000 | 317,000 |
| Q3 2021 | 215,000 | 839,000 |
| Q4 2021 | 180,000 | 990,000 |
| Q1 2022 | 276,000 | 1,103,000 |
| Q2 2022 | 117,000 | 283,000 |
| Q3 2022 | 203,000 | 135,000 |
| Q4 2022 | 6,491,574 | 3,634,628 |
| Q1 2023 | 1,315,834,000 | 33,013,000 |